• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对事先授权负担的认知及解决方案。

Perceptions of prior authorization burden and solutions.

作者信息

Sahni Nikhil R, Istvan Brooke, Stafford Celia, Cutler David

机构信息

Department of Economics, Harvard University, Cambridge, MA, 02138, United States.

Center for US Healthcare Improvement, McKinsey & Company, Boston, MA 02110, United States.

出版信息

Health Aff Sch. 2024 Aug 6;2(9):qxae096. doi: 10.1093/haschl/qxae096. eCollection 2024 Sep.

DOI:10.1093/haschl/qxae096
PMID:39328396
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11425057/
Abstract

The prior authorization (PA) process consumes time and money on the part of patients, providers, and payers. While some research shows substantial possible savings in the PA process, identifying what different groups can do is not as well known. Thus, organizations have struggled to capture this opportunity. To understand different perspectives on PA burden and receptivity to possible changes in the PA process, we surveyed 1005 patients, 1010 provider employees, and 115 private payer employees. Patients reported the longest perceived wait times but indicated the highest perceived approval rates and lowest perceived burden. The relatively low burden for patients is because most do not have to engage in PA directly. Provider respondents reported spending time equivalent of more than 100 000 full-time registered nurses per year on prior authorization. Artificial intelligence (AI) represents a possible solution: 65% of private payer respondents reported that their organizations planned to incorporate AI into the process in the next 3 to 5 years. Intended adoption by provider respondents is much smaller (11%). Private payer respondents cited cybersecurity concerns and a lack of technical infrastructure as barriers; provider respondents cited lack of budget and limited trust in the technology.

摘要

预先授权(PA)流程耗费了患者、医疗服务提供者和支付方的时间与金钱。虽然一些研究表明PA流程有可能大幅节省开支,但不同群体能采取什么措施却鲜为人知。因此,各机构一直在努力抓住这一机遇。为了解对PA负担的不同看法以及对PA流程可能变化的接受程度,我们对1005名患者、1010名医疗服务提供者员工和115名私人支付方员工进行了调查。患者报告的感知等待时间最长,但表示感知批准率最高且感知负担最低。患者负担相对较低是因为大多数患者无需直接参与PA。医疗服务提供者受访者报告称,他们每年在预先授权方面花费的时间相当于超过10万名全职注册护士的工作时间。人工智能(AI)可能是一种解决方案:65%的私人支付方受访者表示,他们的机构计划在未来3至5年内将AI纳入该流程。医疗服务提供者受访者的预期采用率则低得多(11%)。私人支付方受访者认为网络安全问题和缺乏技术基础设施是障碍;医疗服务提供者受访者则提到缺乏预算和对该技术的信任有限。

相似文献

1
Perceptions of prior authorization burden and solutions.对事先授权负担的认知及解决方案。
Health Aff Sch. 2024 Aug 6;2(9):qxae096. doi: 10.1093/haschl/qxae096. eCollection 2024 Sep.
2
A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.支付方和提供方对胆固醇管理看法的区域性分析:以 PCSK9 抑制剂为例的协同作用模式。
J Manag Care Spec Pharm. 2020 Dec;26(12):1517-1528. doi: 10.18553/jmcp.2020.26.12.1517.
3
4
Perceptions of prior authorization by use of electronic prior authorization software: A survey of providers in the United States.使用电子预先授权软件对预先授权的认知:对美国提供者的调查。
J Manag Care Spec Pharm. 2022 Oct;28(10):1121-1128. doi: 10.18553/jmcp.2022.28.10.1121.
5
The Patient Experience of Prior Authorization for Cancer Care.癌症治疗预先授权的患者体验。
JAMA Netw Open. 2023 Oct 2;6(10):e2338182. doi: 10.1001/jamanetworkopen.2023.38182.
6
Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.支付方视角下的医疗决策中的患者报告结局:肿瘤学示例。
J Manag Care Spec Pharm. 2017 Feb;23(2):125-134. doi: 10.18553/jmcp.2017.23.2.125.
7
Prior authorization as a utilization management tool for elective superficial venous procedures results in high administrative cost and low efficacy in reducing utilization.择期浅表静脉手术的预授权作为一种利用管理工具,导致行政成本高,降低利用率的效果低。
J Vasc Surg Venous Lymphat Disord. 2020 May;8(3):383-389.e1. doi: 10.1016/j.jvsv.2019.10.016. Epub 2019 Dec 17.
8
Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.北卡罗来纳医疗补助计划中,药剂师和医生对质子泵抑制剂即时预先授权计划的满意度以及改用首选药物的比例。
J Manag Care Pharm. 2010 May;16(4):250-63. doi: 10.18553/jmcp.2010.16.4.250.
9
AMCP Partnership Forum: Optimizing Prior Authorization for Appropriate Medication Selection.AMCP 合作论坛:优化适当药物选择的预先授权。
J Manag Care Spec Pharm. 2020 Jan;26(1):55-62. doi: 10.18553/jmcp.2020.26.1.55.
10
Streamlining and Reimagining Prior Authorization Under Value-Based Contracts: A Call to Action From the Value in Healthcare Initiative's Prior Authorization Learning Collaborative.简化并重塑基于价值的合同下的预先授权:医疗保健价值倡议预先授权学习协作组织的行动呼吁。
Circ Cardiovasc Qual Outcomes. 2020 Jul;13(7):e006564. doi: 10.1161/CIRCOUTCOMES.120.006564. Epub 2020 Jul 20.

引用本文的文献

1
Socio-demographic and clinical factors associated with the receipt of anti-obesity medication prescriptions and metabolic and bariatric surgery among eligible all of Us participants.在符合条件的“我们所有人”研究参与者中,与接受抗肥胖药物处方以及代谢和减肥手术相关的社会人口学和临床因素。
Diabetes Obes Metab. 2025 Sep;27(9):4978-4988. doi: 10.1111/dom.16544. Epub 2025 Jun 19.

本文引用的文献

1
Active steps to reduce administrative spending associated with financial transactions in US health care.采取积极措施减少美国医疗保健领域与金融交易相关的行政开支。
Health Aff Sch. 2023 Oct 11;1(5):qxad053. doi: 10.1093/haschl/qxad053. eCollection 2023 Nov.
2
Comparison of prior authorization across insurers: cross sectional evidence from Medicare Advantage.比较不同保险公司的预先授权:来自 Medicare Advantage 的横断面证据。
BMJ. 2024 Mar 7;384:e077797. doi: 10.1136/bmj-2023-077797.
3
Prior Authorization and Association With Delayed or Discontinued Prescription Fills.
事前授权与处方延迟或中断的关联。
J Clin Oncol. 2024 Mar 10;42(8):951-960. doi: 10.1200/JCO.23.01693. Epub 2023 Dec 12.
4
AI Alone Will Not Reduce the Administrative Burden of Health Care.仅靠人工智能无法减轻医疗保健的行政负担。
JAMA. 2023 Dec 12;330(22):2159-2160. doi: 10.1001/jama.2023.23809.
5
Artificial Intelligence in U.S. Health Care Delivery.美国医疗保健服务中的人工智能
N Engl J Med. 2023 Jul 27;389(4):348-358. doi: 10.1056/NEJMra2204673.
6
Prior Authorization in Total Joint Arthroplasty: A Survey of the American Association of Hip and Knee Surgeons Membership.全膝关节置换术的预先授权:美国髋关节和膝关节外科医师协会会员调查。
J Arthroplasty. 2023 Jul;38(7):1203-1208.e3. doi: 10.1016/j.arth.2023.01.022. Epub 2023 Jan 26.
7
Improving Prior Authorization in Medicare Advantage.改善医疗保险优势计划中的预先授权流程。
JAMA. 2022 Oct 18;328(15):1497-1498. doi: 10.1001/jama.2022.17732.
8
Perceptions of prior authorization by use of electronic prior authorization software: A survey of providers in the United States.使用电子预先授权软件对预先授权的认知:对美国提供者的调查。
J Manag Care Spec Pharm. 2022 Oct;28(10):1121-1128. doi: 10.18553/jmcp.2022.28.10.1121.
9
Evaluation of the Fast Prior Authorization Technology Highway.快速预先授权技术高速公路评估。
J Am Pharm Assoc (2003). 2022 Nov-Dec;62(6):1843-1847. doi: 10.1016/j.japh.2022.07.011. Epub 2022 Aug 9.
10
Measuring the Scope of Prior Authorization Policies: Applying Private Insurer Rules to Medicare Part B.测量预先授权政策的范围:将私人保险公司的规定应用于医疗保险 B 部分。
JAMA Health Forum. 2021 May 28;2(5):e210859. doi: 10.1001/jamahealthforum.2021.0859. eCollection 2021 May.